Innate Pharma gains rights to AZ’s recently approved leukaemia drug
Pharmaphorum Media Limited | October 24, 2018
France’s Innate Pharma has gained rights to AstraZeneca’s recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago. The companies announced a deal in April 2015, which included combining Innate’s IPH2201, an antibody designed to stimulate natural killer cells to attack cancer, with AZ���s checkpoint inhibitor Imfinzi (durvalumab). Under the new agreement, AZ will take a 9.8% equity stake in the French biotech as part of the deal strengthening its presence in immuno-oncology.